Gaojie Fu, Maoting Liu, Zenghao Bi, Jing Mo, Liang Leng, Dan Sun, Shilin Chen
Rhizoma coptidis (RC), known as Huang Lian, is widely used for treating diabetes in Traditional Chinese Medicine. G protein-coupled bile acid receptor 1 (TGR5) is a potential therapeutic target for glucose-lipid metabolic disorders due to its capacity to stimulate glucagon-like peptide-1 (GLP-1) secretion. However, whether RC contains ingredients targeting TGR5 remains unclear. In this study, we screened 330 secondary metabolites of RC via molecular docking and identified obacunone as a top candidate. We confirmed binding using Cell Membrane Chromatography (CMC) and quantified affinity via Surface Plasmon Resonance (SPR), determining a KD of 101 μM. cAMP assays identified obacunone as an activator of TGR5. Subsequently, concentration-dependent cAMP assays characterized it as a partial agonist with an EC50 of 9.6 μM. Finally, transcriptomic profiling revealed a stress adaptation response, identifying Heme Oxygenase 1 (HMOX1) as the most significantly upregulated gene (padj = 9.99 × 10−72, log2FoldChange = 1.65). These findings contribute to understanding the pharmacological profile of RC and provide a screening example for identifying components with GPCR activity in RC.